NZ603999A - Treatment of autoimmune diseases - Google Patents

Treatment of autoimmune diseases

Info

Publication number
NZ603999A
NZ603999A NZ603999A NZ60399911A NZ603999A NZ 603999 A NZ603999 A NZ 603999A NZ 603999 A NZ603999 A NZ 603999A NZ 60399911 A NZ60399911 A NZ 60399911A NZ 603999 A NZ603999 A NZ 603999A
Authority
NZ
New Zealand
Prior art keywords
treatment
amino
autoimmune diseases
phenylsulfanyl
benzyloxy
Prior art date
Application number
NZ603999A
Other languages
English (en)
Inventor
Peter Gergely
Erik Wallstroem
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42199281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ603999(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ603999A publication Critical patent/NZ603999A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/30Sulfides having the sulfur atom of at least one thio group bound to two carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ603999A 2010-05-06 2011-05-05 Treatment of autoimmune diseases NZ603999A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10162079 2010-05-06
PCT/EP2011/057203 WO2011138393A1 (en) 2010-05-06 2011-05-05 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
NZ603999A true NZ603999A (en) 2014-06-27

Family

ID=42199281

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ603999A NZ603999A (en) 2010-05-06 2011-05-05 Treatment of autoimmune diseases

Country Status (24)

Country Link
US (1) US20130172297A1 (enExample)
EP (1) EP2566470A1 (enExample)
JP (1) JP2013530937A (enExample)
KR (1) KR20130066630A (enExample)
CN (1) CN102869353A (enExample)
AU (1) AU2011249784B2 (enExample)
BR (1) BR112012028190A2 (enExample)
CA (1) CA2795394A1 (enExample)
CL (1) CL2012003091A1 (enExample)
CR (1) CR20120566A (enExample)
CU (1) CU20120154A7 (enExample)
EA (1) EA201201514A1 (enExample)
EC (1) ECSP12012312A (enExample)
IL (1) IL222690A0 (enExample)
MA (1) MA34285B1 (enExample)
MX (1) MX2012012926A (enExample)
NZ (1) NZ603999A (enExample)
PE (1) PE20130612A1 (enExample)
PH (1) PH12012502418A1 (enExample)
SG (1) SG185746A1 (enExample)
TN (1) TN2012000509A1 (enExample)
TW (1) TW201201814A (enExample)
WO (1) WO2011138393A1 (enExample)
ZA (1) ZA201207710B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519539B (zh) * 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
US9289494B2 (en) * 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE463478T1 (de) * 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
AU2002332289B2 (en) 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
AU2003264430B2 (en) 2002-09-19 2009-03-19 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
DK1602660T3 (da) * 2003-02-18 2011-05-23 Kyorin Seiyaku Kk Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer
WO2004103968A1 (en) * 2003-05-26 2004-12-02 Aponetics Ag Sulfopyrroles
MXPA06002349A (es) 2003-08-28 2006-05-22 Novartis Ag Derivados de aminopropanol.
US20070167505A1 (en) * 2004-02-11 2007-07-19 Basilea Pharmaceutica Ag Substituted benzimidazoles and their use for inducing apoptosis
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
NZ588372A (en) * 2005-09-09 2012-03-30 Novartis Ag Diphenyl ether or thioether derivatives for treatment of autoimmune diseases

Also Published As

Publication number Publication date
BR112012028190A2 (pt) 2016-08-02
AU2011249784B2 (en) 2014-03-06
TN2012000509A1 (en) 2014-04-01
US20130172297A1 (en) 2013-07-04
EP2566470A1 (en) 2013-03-13
CA2795394A1 (en) 2011-11-10
PE20130612A1 (es) 2013-06-06
JP2013530937A (ja) 2013-08-01
WO2011138393A1 (en) 2011-11-10
AU2011249784A1 (en) 2012-12-20
CN102869353A (zh) 2013-01-09
CU20120154A7 (es) 2013-03-27
KR20130066630A (ko) 2013-06-20
ECSP12012312A (es) 2012-12-28
PH12012502418A1 (en) 2018-03-21
SG185746A1 (en) 2013-01-30
MX2012012926A (es) 2012-12-17
CR20120566A (es) 2013-01-09
EA201201514A1 (ru) 2013-05-30
CL2012003091A1 (es) 2013-03-22
TW201201814A (en) 2012-01-16
MA34285B1 (fr) 2013-06-01
ZA201207710B (en) 2013-06-26
IL222690A0 (en) 2012-12-31

Similar Documents

Publication Publication Date Title
BR112014018879A8 (pt) Composto e composição farmacêutica e combinação compreendendo dito composto
BR112017010188A2 (pt) análogos de éter fosfolipídeos como veículos de fármacos alvejando câncer
MY186106A (en) Diagnosis, prevention and treatment of diseases of the joint
EP4316305A3 (en) Sole system having movable protruding members
BR112013000501A2 (pt) revestimentos exteriores flexíveis reutilizáveis para elementos de inserção absorventes descartáveis
AU2016204216A1 (en) Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
MX341732B (es) Inhibidores de la demetilasa lsd1 basados en arilciclopropilamina y sus usos médicos.
BR112014013930A2 (pt) proteção para bomba tira-leite e bomba tira-leite
BR112013029271A2 (pt) cicatrização de tecido
MX2012013812A (es) Suela transparente asociada con plantilla interna de gel con ovalos amortiguadores comunes que amortiguan el impacto al caminar.
CY1115455T1 (el) Χρησιμοποιηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια του πονου νευροπαθειας
BR112013012621A2 (pt) heterociclos microbicidas
BR112013000433A2 (pt) diagnóstico e tratamento de câncer de mama
BR112012033388A2 (pt) compostos para o tratamento de distúrbios e doenças de segmento posterior
GB2507906A (en) Localized physiologic status from luminosity around fingertip or toe
BR112012027550A2 (pt) uso de uma composição
BR112014006559A2 (pt) derivados do ácido betulínico com atividade antiviral
BR112013020419A2 (pt) microbicidas derivados de pirazol
BR112015025719A2 (pt) terapia contra o câncer
BR112014019399A2 (pt) métodos de tratamento da fibrose
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
BR112014017902A2 (pt) Agente terapêutico ou profilático para doenças causadas por distúrbios do metabolismo de glicose
MY194604A (en) Guanidinobenzoic acid ester compound
BR112013020781A2 (pt) emprego de um implante médico como barreira de adesão
SE1500342A1 (en) New bandage

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH

Effective date: 20140409

PSEA Patent sealed
LAPS Patent lapsed